WARPTECHNEWS · LAB

Home AI Business Tech Archive

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

Home
Archivio
Editor's Brief
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Storia in 11 fonti

FDA Approval Adds New Cholesterol Treatment Option in Merck Portfolio - Merck & Co (NYSE:MRK)

Merck's Lipfendra wins FDA approval as the first oral PCSK9 inhibitor for adults with high LDL cholesterol after positive Phase 3 results.

Raccontata da

biopharmadive.com

medpagetoday.com

economictimes.indiatimes.com

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo5 h fa

FDA Approval Adds New Cholesterol Treatment Option in Merck Portfolio - Merck & Co (NYSE:MRK)

Merck's Lipfendra wins FDA approval as the first oral PCSK9 inhibitor for adults with high LDL cholesterol after positive Phase 3 results.

Timeline cronologica

giovedì 16 luglio 2026·biopharmadive.com
Merck wins first approval of a PCSK9 cholesterol pill
The speedy clearance of Lipfendra is an important milestone for Merck and the result of a controversial voucher program put in place by former commissioner Marty Makary.
giovedì 16 luglio 2026·healio.com
FDA approves Lipfendra, the first oral PCSK9 inhibitor, to lower LDL
Merck and the FDA announced the approval of enlicitide 20 mg as an add-on to diet and exercise to lower LDL in adults with hypercholesterolemia and those with heterozygous…

biopharmadive.com

1 g fa

Merck wins first approval of a PCSK9 cholesterol pill

The speedy clearance of Lipfendra is an important milestone for Merck and the result of a controversial voucher program put in place by former commissioner Marty Makary.

Leggi questa versione → originale

economictimes.indiatimes.com5 h fa

Merck gets US FDA nod for first-in-its-class oral cholesterol drug

The U.S. FDA has approved Merck's new cholesterol-lowering pill, Lipfendra. This oral medication works by blocking the PCSK9 protein, which helps lower bad cholesterol. Lipfendra offers an alternative for patients who…

Leggi questa versione → originale

nbcnews.com11 h fa

FDA approves new kind of cholesterol pill

Merck’s pill, called Lipfendra, is a PCSK9 inhibitor, which works in a different way than a statin to lower cholesterol.

Leggi questa versione → originale

healio.com1 g fa

FDA approves Lipfendra, the first oral PCSK9 inhibitor, to lower LDL

Merck and the FDA announced the approval of enlicitide 20 mg as an add-on to diet and exercise to lower LDL in adults with hypercholesterolemia and those with heterozygous familial hypercholesterolemia.Enlicitide…

Leggi questa versione → originale

FDA approves first pill to significantly lower 'bad' cholesterol - UPI.com

The Food and Drug Administration on Thursday approved Merck's Lipfendra, which some have hailed as a breakthrough in cholesterol management.

Leggi questa versione → originale

giovedì 16 luglio 2026·

endpoints.news

Merck beats AstraZeneca to first approval for first PCSK9 pill

Merck's Lipfendra beats AstraZeneca's laroprovstat to become the first oral PCSK9 pill, priced at $10.50/day with $370M in 2027 sales forecast.

giovedì 16 luglio 2026·

medpagetoday.com

FDA Approves First PCSK9 Inhibitor in Pill Form

With enlicitide, large LDL cholesterol reductions possible without a needle

giovedì 16 luglio 2026·

cnn.com

Merck’s cholesterol pill gets US FDA approval | CNN

Merck said on Thursday the U.S. FDA has approved its cholesterol pill, the first of its kind to receive the health regulator’s nod, bolstering the drugmaker’s efforts to…

giovedì 16 luglio 2026·

nbcnews.com

FDA approves new kind of cholesterol pill

Merck’s pill, called Lipfendra, is a PCSK9 inhibitor, which works in a different way than a statin to lower cholesterol.

giovedì 16 luglio 2026·

benzinga.com

FDA Approval Adds New Cholesterol Treatment Option in Merck Portfolio - Merck & Co (NYSE:MRK)

Merck's Lipfendra wins FDA approval as the first oral PCSK9 inhibitor for adults with high LDL cholesterol after positive Phase 3 results.

giovedì 16 luglio 2026·

economictimes.indiatimes.com

Merck gets US FDA nod for first-in-its-class oral cholesterol drug

The U.S. FDA has approved Merck's new cholesterol-lowering pill, Lipfendra. This oral medication works by blocking the PCSK9 protein, which helps lower bad cholesterol. Lipfendra…

giovedì 16 luglio 2026·

fortune.com

The cholesterol shot you couldn’t afford is now a pill | Fortune

The FDA has cleared Merck’s Lipfendra for patients whose artery‑clogging cholesterol remains high despite statins.

giovedì 16 luglio 2026·

upi.com

FDA approves first pill to significantly lower 'bad' cholesterol - UPI.com

The Food and Drug Administration on Thursday approved Merck's Lipfendra, which some have hailed as a breakthrough in cholesterol management.

venerdì 17 luglio 2026·

abcnews.com

FDA approves 1st-of-its-kind pill to reduce cholesterol

The Food and Drug Administration (FDA) approved on Thursday a first-of-its-kind oral option that can lower "bad" LDL cholesterol with a daily pill instead of a shot.